SCHEMBL26269274

SCHEMBL26269274

CC[C@H]1O[C@H](OC(=O)c2ccccc2)[C@@H](F)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 2/20 0.44
▸ LGALS9 O00182 1/20 0.44
▸ LGALS1 P09382 1/20 0.44
▸ LGALS7; LGALS7B P47929 1/20 0.44
▸ LMNA P02545 1/20 0.39
▸ PTPN1 P18031 4/20 0.38
▸ NT5E P21589 1/20 0.38
▸ CHRNA7 P36544 1/20 0.37
▸ TSHR P16473 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ BCHE P06276 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12139431 1.00 LGALS3 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL14586559 1.00 LGALS3 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL10005361 1.00 LGALS3 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL14586558 0.88 LGALS9 (0.43) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL14305544 0.88 LGALS3 (0.54) LGALS3LGALS9LGALS1LGALS7; LGALS7BPTPN1
SCHEMBL14618095 0.87 LGALS3 (0.43) LGALS3LGALS9LGALS1LGALS7; LGALS7BPTPN1
SCHEMBL15385703 0.86 LGALS9 (0.39) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL12151652 0.86 LGALS9 (0.39) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL10026377 0.86 LGALS9 (0.39) LGALS3LGALS9LGALS1LGALS7; LGALS7BLMNA
SCHEMBL4785477 0.85 PTPN1 (0.54) LGALS3LGALS9LGALS1LGALS7; LGALS7BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 LGALS3 4024/4885LGALS9 2986/4885LGALS1 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback